null

null

null

null

Near-zero debt; equity-financed clinical-stage biotech with ~$10M cash runway; 20% rate rise immaterial to interest expense

Minimal direct sensitivity; no significant floating-rate debt; higher rates increase equity dilution cost and discount future cash flows

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) API sourcing from European chemical suppliers (regulatory/geopolitical risk); 2) Single-source synthesis of Berubicin from limited CMOs

No meaningful international revenue; USD-functional company; sovereign currency devaluation exposure is effectively nil currently

Operations US-based; clinical trials in US/Europe; no international revenue streams generating material FX exposure

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single CMO for Berubicin synthesis; likely >50% of drug supply input from non-substitutable source short-term

Clinical-stage pharma; no cloud infrastructure dependency for core operations; trial data managed via CRO platforms, not proprietary cloud

Secondary reliance on CRO (contract research organizations) for trial execution; termination risk manageable with 60–90 day transition

Low API coupling risk to tech vendors; high switching cost to change CMO or CRO mid-trial due to FDA continuity and validation requirements

Revenue model is drug licensing/royalties post-approval; equity is standard registered security; Howey Test not applicable to revenue model

Very High

Limited patient data held internally; CROs handle PHI; GDPR exposure exists for EU trial sites but is contractually delegated to CROs

Negligible antitrust risk; single-asset pre-revenue biotech with no market share in commercialized oncology segments

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

0% recurring revenue currently; 100% transactional/milestone-based future model (licensing, royalties, grants); pre-commercial stage

Primary monetization via drug licensing deals, potential royalty streams, and eventual product sales post-FDA approval

No established pricing; future oncology drug pricing likely $100K–$300K/course based on glioblastoma market comparables

High theoretical pricing power in orphan/rare CNS oncology market with limited competition and high unmet need

Target gross margin 70–85% post-commercialization, consistent with specialty oncology drug peers

No free-rider risk; pipeline asset is patented; no subscription or freemium model exists

Headcount-sublinear growth model; commercialization via partners/licensees means revenue can scale without proportional headcount increase

Marginal cost of revenue growth is low post-approval if licensed; high pre-approval due to fixed clinical trial burn rate

No franchise network; not applicable

At 10x scale, customer is insurer/hospital system; CAC replaced by partnership/licensing deal cost; unit economics depend on royalty rate negotiated

No network effects; drug efficacy is standalone; value does not increase with additional users

AI displacement risk low; CNS drug discovery benefits from AI tools but core IP is chemistry/biology not displaceable near-term

Moderate-high resilience; glioblastoma treatment demand is inelastic, but funding/licensing deals may slow in severe credit contraction

Primary future customer: oncology specialty hospitals and academic medical centers treating glioblastoma patients

Secondary: pharmaceutical licensing partners and payers (insurance/Medicare) covering CNS oncology treatments

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital allocated entirely to future-state R&D (clinical trials); no legacy infrastructure; capex is pure pipeline investment with no reallocation drag

0001729427

CNSP